187 related articles for article (PubMed ID: 22947000)
1. What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?
Donnelly OG; Melcher AA; Vile RG; Pulido J
Immunotherapy; 2012 Aug; 4(8):749-51. PubMed ID: 22947000
[No Abstract] [Full Text] [Related]
2. Advances in the treatment of melanoma.
Lacy KE; Karagiannis SN; Nestle FO
Clin Med (Lond); 2012 Apr; 12(2):168-71. PubMed ID: 22586796
[No Abstract] [Full Text] [Related]
3. Industry makes strides in melanoma.
Garber K
Nat Biotechnol; 2010 Aug; 28(8):763-4. PubMed ID: 20697383
[No Abstract] [Full Text] [Related]
4. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.
Wolchok J
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii15-21. PubMed ID: 22918923
[TBL] [Abstract][Full Text] [Related]
5. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
6. The conquest of melanoma by immunotherapy.
Lejeune FJ
Melanoma Res; 2015 Oct; 25(5):373-5. PubMed ID: 26173006
[No Abstract] [Full Text] [Related]
7. Vemurafenib and ipilimumab: new agents for metastatic melanoma.
Banaszynski M; Kolesar JM
Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456
[TBL] [Abstract][Full Text] [Related]
8. First Oncolytic Viral Therapy for Melanoma.
Poh A
Cancer Discov; 2016 Jan; 6(1):6. PubMed ID: 26552414
[TBL] [Abstract][Full Text] [Related]
9. New targeted therapies in melanoma.
Kudchadkar RR; Gonzalez R; Lewis K
Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
[TBL] [Abstract][Full Text] [Related]
10. Narrowing the knowledge gaps for melanoma.
Slipicevic A; Herlyn M
Ups J Med Sci; 2012 May; 117(2):237-43. PubMed ID: 22339359
[TBL] [Abstract][Full Text] [Related]
11. [New paradigms and metaphors in cutaneous melanoma treatment].
Piérard GE; Nizet JL; Humbert P
Rev Med Liege; 2016 Dec; 71(12):562-566. PubMed ID: 28387097
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
Lens M; Testori A; Ferucci PF
Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab and vemurafenib: two different routes for targeting melanoma.
Burgeiro A; Mollinedo F; Oliveira PJ
Curr Cancer Drug Targets; 2013 Oct; 13(8):879-94. PubMed ID: 23862981
[TBL] [Abstract][Full Text] [Related]
15. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
16. Drug development: a chance of survival.
Hoag H
Nature; 2014 Nov; 515(7527):S118-20. PubMed ID: 25407709
[No Abstract] [Full Text] [Related]
17. Immunotherapy in melanoma.
Feld E; Mitchell TC
Immunotherapy; 2018 Aug; 10(11):987-998. PubMed ID: 30149766
[TBL] [Abstract][Full Text] [Related]
18. [BRAF mutation: a novel approach in targeted melanoma therapy].
Arenbergerová M; Puzanov I
Klin Onkol; 2012; 25(5):323-8. PubMed ID: 23102192
[TBL] [Abstract][Full Text] [Related]
19. [Major therapeutic advances in the treatment of metastatic melanoma].
Mateus C; Robert C
Bull Cancer; 2012 Jun; 99(6):619-25. PubMed ID: 22652330
[TBL] [Abstract][Full Text] [Related]
20. [Melanoma- finally good news].
Wicki A; Arnold AW; Itin PH; Zippelius A
Praxis (Bern 1994); 2013 May; 102(11):667-70. PubMed ID: 23692905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
